Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Forw
Post# of 421
(Total Views: 176)
Posted On: 12/02/2022 4:56:23 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Forward With Exploration of Patented DehydraTECH(TM)-Processed CBD for Dementia
- Approximately 55 million people worldwide have dementia, which is expected to grow to 78 million by 2030
- The dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029
- Clinical studies have established a connection between hypertension and dementia
- With DehydraTECH(TM)-CBD already evidencing that it can lower blood pressure and its propensity to cross the blood-brain barrier, Lexaria is investigating the potential for a positive outcome in the DEM-A22-1 study
According to the World Health Organization (“WHO”), dementia is the seventh leading cause of death among all diseases and one major cause of disability and dependency among older people worldwide. Dementia is characterized by the deterioration of cognitive function, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. Although consciousness is not impaired, it is commonly accompanied by mood changes, emotional control deficits, behavior changes, and motivational impairments. It is estimated that approximately 55 million people have dementia worldwide, a number expected to grow to 78 million by 2030 (https://nnw.fm/STOC0 ).
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for use against dementia. As previously evidenced in animal studies, DehydraTECH-CBD crosses the blood-brain barrier much more effectively than originally thought possible.
Clinical studies have established a connection between hypertension and dementia – individuals who have high blood pressure are more likely to develop vascular dementia, which is the second most common form of dementia, following Alzheimer’s Disease. Vascular dementia is caused by a reduced blood flow to the brain, starving brain cells of oxygen and nutrients needed to function properly. Previous studies of DehydraTECH-CBD for potential hypertension treatment have proved successful with no adverse reactions experienced by subjects in the human trials.
The company recently announced the launch of its first-ever study to investigate DehydraTECH-CBD and dementia (DEM-A22-1). Given the propensity of DehydraTECH-CBD to cross the blood-brain barrier, the established fact that it lowers human blood pressure, and CBD’s vasodilation properties, Lexaria is eager to investigate the potential of DehydraTECH-CBD’s positive effects on dementia (https://nnw.fm/BDDsW ).
Based on research conducted by Maximize Marketing Research (“MMR”), the dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029. An increase in R&D expenditures, increased frequency of Alzheimer’s Disease indications, a surge in the geriatric population, an upsurge in awareness about neurodegenerative diseases in emerging countries, and a rich pipeline of new treatment alternatives are expected to drive the market during the forecast period (https://nnw.fm/Eed6x ).
The DEM-A22-1 study is a dose-ranging, two-month program involving a total of 32 Long Evans rats that will be dosed with DehydraTECH-CBD. A novel object recognition test, commonly used to assess memory in rodents, is being used to investigate whether CBD enables cognitive performance enhancements in the test model. The study is being undertaken by a third-party testing laboratory in Canada, with expected completion in late January 2023, with data and reporting to follow shortly after. Depending on the study’s outcome, additional investigation into DehydraTECH-processed nicotine (another agent evidenced to enhance cognitive performance) may follow. Lexaria will provide updates on DEM-A22-1 as they become available.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Approximately 55 million people worldwide have dementia, which is expected to grow to 78 million by 2030
- The dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029
- Clinical studies have established a connection between hypertension and dementia
- With DehydraTECH(TM)-CBD already evidencing that it can lower blood pressure and its propensity to cross the blood-brain barrier, Lexaria is investigating the potential for a positive outcome in the DEM-A22-1 study
According to the World Health Organization (“WHO”), dementia is the seventh leading cause of death among all diseases and one major cause of disability and dependency among older people worldwide. Dementia is characterized by the deterioration of cognitive function, affecting memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. Although consciousness is not impaired, it is commonly accompanied by mood changes, emotional control deficits, behavior changes, and motivational impairments. It is estimated that approximately 55 million people have dementia worldwide, a number expected to grow to 78 million by 2030 (https://nnw.fm/STOC0 ).
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for use against dementia. As previously evidenced in animal studies, DehydraTECH-CBD crosses the blood-brain barrier much more effectively than originally thought possible.
Clinical studies have established a connection between hypertension and dementia – individuals who have high blood pressure are more likely to develop vascular dementia, which is the second most common form of dementia, following Alzheimer’s Disease. Vascular dementia is caused by a reduced blood flow to the brain, starving brain cells of oxygen and nutrients needed to function properly. Previous studies of DehydraTECH-CBD for potential hypertension treatment have proved successful with no adverse reactions experienced by subjects in the human trials.
The company recently announced the launch of its first-ever study to investigate DehydraTECH-CBD and dementia (DEM-A22-1). Given the propensity of DehydraTECH-CBD to cross the blood-brain barrier, the established fact that it lowers human blood pressure, and CBD’s vasodilation properties, Lexaria is eager to investigate the potential of DehydraTECH-CBD’s positive effects on dementia (https://nnw.fm/BDDsW ).
Based on research conducted by Maximize Marketing Research (“MMR”), the dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029. An increase in R&D expenditures, increased frequency of Alzheimer’s Disease indications, a surge in the geriatric population, an upsurge in awareness about neurodegenerative diseases in emerging countries, and a rich pipeline of new treatment alternatives are expected to drive the market during the forecast period (https://nnw.fm/Eed6x ).
The DEM-A22-1 study is a dose-ranging, two-month program involving a total of 32 Long Evans rats that will be dosed with DehydraTECH-CBD. A novel object recognition test, commonly used to assess memory in rodents, is being used to investigate whether CBD enables cognitive performance enhancements in the test model. The study is being undertaken by a third-party testing laboratory in Canada, with expected completion in late January 2023, with data and reporting to follow shortly after. Depending on the study’s outcome, additional investigation into DehydraTECH-processed nicotine (another agent evidenced to enhance cognitive performance) may follow. Lexaria will provide updates on DEM-A22-1 as they become available.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)